Bone Regeneration Market Size, Share, By Product Type (Bone Grafts and Substitutes, Bone Growth Stimulators, and Others), Material (Natural, and Synthetic), Application (Oral and Maxillofacial Surgeries, Spinal Fusion Surgeries, Joint Reconstruction, Trauma and Fracture Repair, and Others), End Use Industry (Hospitals, Specialty Clinics, and Others), and Region - Trends, Analysis, and Forecast till 2035

Report Code: PMI594825 | Publish Date: July 2025 | No. of Pages: 169

Bone Regeneration Market Companies

Stryker Corporation, Medtronic plc, Baxter, The Orthopaedic Implant Company, Bioventus LLC, and others are major participants in the bone regeneration market. Businesses involved in bone regeneration are focusing on innovation through cutting-edge technologies like 3D printing and stem cell therapies in order to speed up research and expand applications. Additionally, they are forming strategic partnerships. They are also diversifying their product lines, buying up smaller companies, and entering emerging markets in an effort to strengthen their position in the market and encourage growth.

List of Key Players in the Market:

  • Stryker Corporation
  • Medtronic plc
  • Zimmer Biomet Holdings, Inc.
  •  Orthofix Medical Inc.
  •  The Orthopaedic Implant Company.
  •  Bioventus LLC
  • Theradaptive, Inc.
  • Orthofix Medical Inc.
  • Baxter
  • Kuros Biosciences
  • Evergen
  • Geistlich Pharma India Pvt. Ltd.
  • B. Braun SE
  • Xtant Medical
  • THERAGEN ETEX CO., LTD.

Recent News:

  • A research team at the National Institute of Technology (NIT) in Rourkela has created a natural bioink that can be used to 3D bioprint structures that resemble bones, on March 2025. The bioink is intended to enhance current bone healing methods by offering a biocompatible and effective substitute for conventional bone grafts and implants.
  • In order to combat bone infections and treat fractures, the Sree Chitra Tirunal Institute for Medical Sciences and Technology has introduced two novel drug-eluting bone graft products to the market, on February 2025. Under the brand names BONYX (for bone infections) and CASPRO (a bioactive, drug-delivering, self-setting bone cement), the goods were created by SCTIMST's Biomedical Technology wing's Department of Biomaterial Science and Technology.